Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
delayed orgasm.
Popular Articles

Individual Health Insurance Market Failing Consumers According To New Report
The individual health insurance market is not a viable option for the majority of uninsured adults, a new report from The Commonwealth Fund finds. Seventy-three percent of people who tried to buy insurance on their own in the last three years did not purchase a policy, primarily because premiums were too high. In addition, among adults with individual coverage or who tried to buy coverage in the past three years, 57 percent said it was very difficult or impossible to find coverage they could afford, 47 percent said it was very difficult or impossible to find a plan with the coverage they needed, and 36 percent were denied coverage or charged more because of a pre-existing condition, or had the condition excluded from their coverage.
generic viagra
Grants To Support Undergraduate And Graduate Nursing Students
The University of Miami (UM) School of Nursing and Health Studies has received two grants totaling over $60,000 from the Department of Health and Human Services" Health Res and Services Administration (HRSA). One grant will provide scholarships to undergraduate students while the other grant will support students in the school"s graduate nurse practitioner programs.
News of the day
Blue Dogs: We Have Agreement With House Dems On Health Bill
Work on the House health care reform bill is slowing as Rep. Henry Waxman of California and fiscally conservative Blue Dog Democrats have come to an agreement on Medicare payments, The New York Times reports.
Nutrition

MiCardia® Announces First U.S. Implant

MiCardia® (MiCardia Corporation, Irvine, California) announced the completion of the first U.S. implant of its Dynaplasty® mitral valve repair technology. The surgery was performed last week at Beaumont Hospital, Royal Oak, Michigan. Francis L. Shannon, M.D., who is a partner in SEMCVS and Director of CV Surgical Research and Quality Outcomes at Beaumont, commented, "The MiCardia® device implanted easily and conformed well to the patient"s mitral annulus. The complete D-shaped ring was used to reinforce a complex repair of a flail leaflet segment using minimally invasive techniques. We are excited to be participating in the DYANA Study and believe Dynaplasty® technology will address a major weakness of current devices, namely their inability to deal with changes in valve shape and function after the initial repair procedure." Commenting on the first U.S. site to enter the study, MiCardia® Chief Executive Officer Paul Molloy said, "This is a major milestone for MiCardia® and we are grateful for Dr. Shannon"s expertise in helping develop this technology. The Dynamic Annuloplasty Activation study involves patients from Europe who receive a device capable of activation post-implant and patients from the U.S. who receive a shape memory device that is not capable of activation. MiCardia® received a 510(k) clearance on the non-active version of its Dynaplasty® System in September 2008. Patient data from both the U.S. and Europe will be submitted toward CE Mark of the Company"s Dynaplasty® devices this year. We expect to complete enrollment and submit six month follow up data from the DYANA Study in Q4 of 2009 as a prelude to European commercialization of the world"s first minimally invasive, beating heart valve repair system." MiCardia® is developing Dynaplasty® technology for the treatment of structural heart disease, focusing initially on mitral and tricuspid valve disorders and as a method of interrupting a major element in the onset and progression of Heart Failure. More than 15m people in Europe and the U.S. are in Heart Failure, of which more than 7m suffer from mitral regurgitation. MiCardia® is a privately held company, founded in 2004 and is developing a completely unique treatment technology that will allow minimally invasive late stage adjustment of cardiac anatomy. Surgical, transcutaneous and entirely non-invasive activation platforms are in advanced development. MiCardia


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009